The FDA has issued an alert based on their findings. Additionally, the agency has approved changes to describe their findings on labeling for pioglitazone-containing medicines, which already contain warnings about the possible risk for bladder cancer.
READ MORE LEGAL NEWS
The latest FDA communication states that “health care professionals should not use pioglitazone in patients with active bladder cancer, and should carefully consider the benefits and risks before using pioglitazone in patients with a history of bladder cancer.”
Pioglitazone is approved to improve blood sugar control, along with diet and exercise, in adults with type 2 diabetes. Pioglitazone works by increasing the body’s sensitivity to insulin, a natural hormone that helps control blood sugar levels. Untreated, type 2 diabetes can lead to serious problems, including blindness, nerve and kidney damage, and heart disease.